633 related articles for article (PubMed ID: 29099487)
1. Why are there hotspot mutations in the TP53 gene in human cancers?
Baugh EH; Ke H; Levine AJ; Bonneau RA; Chan CS
Cell Death Differ; 2018 Jan; 25(1):154-160. PubMed ID: 29099487
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
4. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
5. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
6. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
8. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
10. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 gain-of-function in cancer.
Oren M; Rotter V
Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
[TBL] [Abstract][Full Text] [Related]
12. Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP.
Srividya ; Giridhar BH; Vishwanath S; Chakraborty A
Pathol Oncol Res; 2019 Oct; 25(4):1373-1377. PubMed ID: 29500733
[TBL] [Abstract][Full Text] [Related]
13. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
14. Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer.
De Souza C; Madden J; Koestler DC; Minn D; Montoya DJ; Minn K; Raetz AG; Zhu Z; Xiao WW; Tahmassebi N; Reddy H; Nelson N; Karnezis AN; Chien J
J Natl Cancer Inst; 2021 Sep; 113(9):1246-1257. PubMed ID: 33555293
[TBL] [Abstract][Full Text] [Related]
15. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein.
Hoyos D; Greenbaum B; Levine AJ
Cell Death Differ; 2022 May; 29(5):938-945. PubMed ID: 35383292
[TBL] [Abstract][Full Text] [Related]
16. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
18. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.
Wang Y; Suh YA; Fuller MY; Jackson JG; Xiong S; Terzian T; Quintás-Cardama A; Bankson JA; El-Naggar AK; Lozano G
J Clin Invest; 2011 Mar; 121(3):893-904. PubMed ID: 21285512
[TBL] [Abstract][Full Text] [Related]
19. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
Balasundaram A; Doss CGP
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
